2017 Winners

The 2017 World ADC Awards winners are:

★Best Platform Technology (sponsored by Ambrx)

Winner: Bicycle Therapeutics
Runner Up: Synaffix

★Most Promising Clinical Candidate

Winner: ImmunoGen (Mirvetuximab soravtansine)
Runner Up: Stemcentrx (Rova-T)

★Best CMO Provider

Winner: Lonza
Runner Up: BSP Pharmaceuticals

★Best New Drug Developer:

Winner: Mersana
Runner Up: Heidelberg Pharma

★Best CRO Provider

Winner: PPD
Runner Up: Syngene International Ltd.

★Best Publication 2016 (sponsored by Medimmune)

Winner: A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy.

Li JY, Perry SR, Muniz-Medina V, Wang X, Wetzel LK, Rebelatto MC, Hinrichs MJ, Bezabeh BZ, Fleming RL, Dimasi N, Feng H, Toader D, Yuan AQ, Xu L, Lin J, Gao C, Wu H, Dixit R, Osbourn JK, Coats SR.

Cancer Cell. 2016 Jan 11;29(1):117-29. doi: 10.1016/j.ccell.2015.12.008.

Runner Up: Targeted drug delivery through the traceless release of tertiary and heteroaryl amines from antibody-drug conjugates.

Staben LR1, Koenig SG1, Lehar SM1, Vandlen R1, Zhang D1, Chuh J1, Yu SF1, Ng C1, Guo J1, Liu Y1, Fourie-O’Donohue A1, Go M1, Linghu X1, Segraves NL1, Wang T2, Chen J2, Wei B1, Phillips GD1, Xu K1, Kozak KR1, Mariathasan S1, Flygare JA1, Pillow TH1.

Nat Chem. 2016 Dec;8(12):1112-1119. doi: 10.1038/nchem.2635.

★Individual Input to the Field 2016

Gregory Winter

★Long Standing Contribution

Jagath Reddy Junutula

★Best Poster Award

Winner: Enzymatic (dual) Site-Specific Conjugation of Engineered & Native Antibodies
Philipp Spycher, Postdoctoral Researcher, Paul Scherrer Institute

Runner Up: A Novel ADC Target with Potential for Treatment of Sarcoma, Glioblastoma & Leukemia: In Vitro & In Vivo Proof Of Concept, & Recent Development Of Highly Potent ADC Species
Christoffer Nielsen, Post Doctoral, The Finsen Laboratory